Cytokinetics (United States)

Cytokinetics (United States)

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Cytokinetics (United States), United States, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

53%


Total
Publications

445


Total Open
Publications

235


Total
Citations

19K


Open Access
Percentage

53%


Total
Publications

445


Total Open
Publications

235


Total
Citations

19K

Wikipedia

Website

download

Breakdown

20% 24% 8% 48%

Publisher Open

20%

Both

24%

Other Platform Open

8%

Closed

48%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

05101520253035404550556065Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

30%OA Journal

OA Journal 30%

59

Hybrid 38%

75

No Guarantees 32%

63

Other Platform Open

Domain 65%

94

Institution 38%

55

Other Internet 26%

37

Public 3%

5

Preprint 1%

1

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
93
DOI
Other Internet
26
University of Florence - Florence Research
Institution
14
Unknown Repository
Other Internet
12
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
11
DANS - Data Archiving and Networked Services
Institution
9
Europe PMC
Domain
6
Figshare
Public
5
Washington University School of Medicine - Digital Commons@Becker
Institution
4
U.S. Department of Energy Office of Scientific and Technical Information - OSTI OAI
Institution
3
1 / 5

Data updated 18 August 2025

Share

Share

Share